Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG2 | P78540 | 6/20 | 1.00 |
| ▸ | ARG1 | P05089 | 4/20 | 1.00 |
| ▸ | GGT1 | P19440 | 4/20 | 0.72 |
| ▸ | GSR | P00390 | 2/20 | 0.59 |
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.47 |
| ▸ | NOS1 | P29475 | 3/20 | 0.47 |
| ▸ | NOS3 | P29474 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | GRM8 | O00222 | 1/20 | 0.46 |
| ▸ | GRM6 | O15303 | 1/20 | 0.46 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.46 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.46 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL215523 | 1.00 | ARG2 (1.00) | ARG2ARG1GGT1GSRNOS2 | |
| Hydrochloric Acid SCHEMBL29572780 | 0.98 | ARG2 (1.00) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL6702426 | 0.93 | ARG2 (0.88) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL6702428 | 0.93 | ARG2 (0.88) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL6704317 | 0.88 | ARG2 (0.78) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL6704320 | 0.88 | ARG2 (0.78) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL30726883 | 0.84 | GGT1 (1.00) | ARG2ARG1GGT1GSRCYP1A2 | |
| SCHEMBL4254049 | 0.84 | GGT1 (1.00) | ARG2ARG1GGT1GSRCYP1A2 | |
| SCHEMBL29268443 | 0.83 | GSR (0.80) | ARG2ARG1GGT1GSRNOS2 | |
| SCHEMBL21689907 | 0.83 | GSR (0.80) | ARG2ARG1GGT1GSRNOS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 941 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4659023-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | Immusmol SAS (FR) | 2025-12-10 | — | — | EP | claimed |
| WO-2024161038-A1 | METHOD OF PREDICTING SUCCESS OF A CANCER THERAPY | IMMUSMOL SAS (FR) | 2024-08-08 | — | — | WO | claimed |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2023-10-10 | — | — | US | claimed |
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | Effector Therapeutics Inc. (US) | 2023-02-14 | — | — | US | claimed |
| WO-2023283332-A1 | USES OF ARGINASE INHIBITORS FOR MANAGING KIDNEY DISEASE AND CARDIOVASCULAR CONDITIONS | EMORY UNIVERSITY (US) | 2023-01-12 | — | — | WO | claimed |
| EP-4069307-A2 | DENDRIMER COMPOSITIONS AND METHODS FOR DRUG DELIVERY | Ashvattha Therapeutics, Inc. (US) | 2022-10-12 | — | — | EP | claimed |
| CN-115103688-A | TRIACETIC N-ACETYLGALAMINE-MODIFIED HYDROXYPOLYAMINOAMINE TRIPLOMERS AND METHODS OF USE THEREOF | 阿什瓦塔治疗股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| CN-115103689-A | Dendrimer compositions and methods for drug delivery | 阿什瓦塔治疗股份有限公司 | 2022-09-23 | — | — | CN | claimed |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | UNIV CASE WESTERN RESERVE (US) | 2022-07-07 | — | — | US | claimed |
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | CASE WESTERN RESERVE UNIVERSITY (US) | 2022-01-25 | — | — | US | claimed |
| EP-1596854-A4 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2007-06-06 | — | — | EP | claimed |
| WO-2006097359-A1 | HAIR AND/OR EYELASH CARE COMPOSITION CONTAINING AMINEXIL IN COMBINATION WITH AN AGENT FOR PROMOTING THE NO PRODUCTION AND USES THEREOF | L'ORÉAL (FR) | 2006-09-21 | — | — | WO | claimed |
| JP-2006518387-A | — | — | 2006-08-10 | — | — | JP | claimed |
| EP-1596854-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | Children's Hospital & Research Center at Oakland (US) | 2005-11-23 | — | — | EP | claimed |
| US-20050158401-A1 | Treatment and diagnosis of conditions associated with elevated arginase activity | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-07-21 | — | — | US | claimed |
| WO-2004073623-A9 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDRENS HOSP & RES CT OAK (US) | 2005-01-27 | — | — | WO | claimed |
| WO-2004073623-A2 | TREATMENT OF CONDITIONS ASSOCIATED WITH DECREASED NITRIC OXIDE BIOAVAILABILITY, INCLUDING ELEVATED ARGINASE CONDITIONS | CHILDREN'S HOSPITAL & RESEARCH CENTER AT OAKLAND (US) | 2004-09-02 | — | — | WO | claimed |
| US-20040057926-A1 | Modulation of the immune response through the manipulation of arginine levels | LSU MEDICAL CENTER | 2004-03-25 | — | — | US | claimed |
| WO-2003078578-A2 | MODULATION OF THE IMMUNE RESPONSE THROUGH THE MANIPULATION OF ARGININE LEVELS | LSU MEDICAL CENTER (US) | 2003-09-25 | — | — | WO | claimed |
| US-6387890-B1 | CARDIOVASCULAR DISORDERS; GASTROINTESTINAL DISORDERS; SEXUAL DISORDERS | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2002-05-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11229685-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | ARG2 50/4885ARG1 225/4885GGT1 1135/4885 |
| US-20220211820-A1 | FUNGAL IRON ACQUISITION INHIBITORS AND USES THEREOF | SLC40A1, SLC30A6, SLC30A7 | ARG2 50/4885ARG1 225/4885GGT1 1135/4885 |
| US-11779634-B2 | Fungal iron acquisition inhibitors and uses thereof | SLC40A1, SLC30A6, SLC30A7 | ARG2 50/4885ARG1 225/4885GGT1 1135/4885 |
| US-11576933-B2 | Compositions and methods for an improved antitumor immune response | EIF4A2, EIF4A1, EIF4EBP1 | ARG2 714/4885ARG1 488/4885GGT1 3005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.